How to Cite
Abstract
Guillain-Barre Syndrome (GBS) is one of the most frequent peripheral neuropathies in the world, which has Campylobacter jejuni infection and some immunizations as the most common triggers; Likewise, it has been possible to determine an antibody-mediated immune response, complement activation and macrophage recruitment against the axons of nerve cells or myelin sheaths of peripheral neurons. According to the clinical criteria, to diagnose GBS the presence of progressive weakness in the extremities is required, as well as arreflexia; additionally, are evaluated: the evolution of the symptoms from 2 to 4 weeks, the presence of sensitive, autonomic and cranial nerve symptoms, bilateral facial weakness, electrodiagnostic findings, albuminocytological dissociation and progressive recovery of symptoms. Treatment continues to be based on the administration of intravenous gamma globulin and plasmapheresis.
Keywords
References
Donofrio PD. Guillain-Barré Syndrome. CONTINUUM: Lifelong Learning in Neurology. 2017 Oct;23(5):1295-1309. https://doi.org/10.1212/con.0000000000000513
Wijdicks EF, Klein CJ. Guillain-Barré Syndrome. Mayo Clinic Proceedings. 2017 03;92(3):467-479. https://doi.org/10.1016/j.mayocp.2016.12.002
Hiew FL, Ramlan R, Viswanathan S, Puvanarajah S. Guillain-Barré Syndrome, variants & forms fruste: Reclassification with new criteria. Clinical Neurology and Neurosurgery. 2017 07;158:114-118. https://doi.org/10.1016/j.clineuro.2017.05.006
Dash S, Pai AR, Kamath U, Rao P. Pathophysiology and diagnosis of Guillain–Barré syndrome – challenges and needs. International Journal of Neuroscience. 2014 05 27;125(4):235-240. https://doi.org/10.3109/00207454.2014.913588
Jasti AK, Selmi C, Sarmiento-Monroy JC, Vega DA, Anaya J, Gershwin ME. Guillain-Barré syndrome: causes, immunopathogenic mechanisms and treatment. Expert Review of Clinical Immunology. 2016 06 21;12(11):1175-1189. https://doi.org/10.1080/1744666x.2016.1193006
Willison HJ, Jacobs BC, van Doorn PA. Guillain-Barré syndrome. The Lancet. 2016 08;388(10045):717-727. https://doi.org/10.1016/s0140-6736(16)00339-1
Guisset F, Ferreiro C, Voets S, Sellier J, Debaugnies F, Corazza F, Deconinck N, Prigogine C. Anti-GQ1b antibody syndrome presenting as acute isolated bilateral ophthalmoplegia: Report on two patients and review of the literature. European Journal of Paediatric Neurology. 2016 05;20(3):439-443. https://doi.org/10.1016/j.ejpn.2016.02.002
Ansar V, Valadi N. Guillain-Barré Syndrome. Primary Care: Clinics in Office Practice. 2015 06;42(2):189-193. https://doi.org/10.1016/j.pop.2015.01.001
Goodfellow JA, Willison HJ. Guillain–Barré syndrome: a century of progress. Nature Reviews Neurology. 2016 Nov 18;12(12):723-731. https://doi.org/10.1038/nrneurol.2016.172
Kuwabara S, Sekiguchi Y, Misawa S. Electrophysiology in Fisher syndrome. Clinical Neurophysiology. 2017 01;128(1):215-219. https://doi.org/10.1016/j.clinph.2016.11.009
Bukhari S, Taboada J. A Case of Miller Fisher Syndrome and Literature Review. Cureus. 2017 02 22;. https://doi.org/10.7759/cureus.1048
Wakerley, B. R., & Yuki, N. (2014). Mimics and chameleons in Guillain-Barré and Miller Fisher syndromes. Practical Neurology, 15(2), 90-99.https://doi.org/10.1136/practneurol-2014-000937
Esposito, S., & Longo, M. R. (2017). Guillain-Barré syndrome. Autoimmunity Reviews, 16(1), 96-101.https://doi.org/10.1016/j.autrev.2016.09.022
Arméstar F , Catalán B, Martínez S. Síndrome de Guillain Barré en la Unidad de Cuidados Intensivos. Rev méd Trujillo 2018;13(2):100-3
Verboon C, van Doorn PA, Jacobs BC. Treatment dilemmas in Guillain-Barré syndrome. Journal of Neurology, Neurosurgery & Psychiatry. 2016 Nov 11;88(4):346-352. https://doi.org/10.1136/jnnp-2016-314862
Tobon, A. (2017). The Role of Immunoglobulin in the Treatment of Immune-Mediated Peripheral Neuropathies. Journal of Infusion Nursing, 40(6), 375-379.
https://doi.org/10.1097/NAN.0000000000000248
Créange A. Guillain-Barré syndrome: 100 years on. Revue Neurologique. 2016 Dec;172(12):770-774. https://doi.org/10.1016/j.neurol.2016.10.011